Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Grifols, S.A.
  6. News
  7. Summary
    GRF   ES0171996087

GRIFOLS, S.A.

(GRF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Grifols and Egypt Inaugurate First African Plasma-Supply Platform, in Cairo, as Part of the Alliance to Attain Self-Sufficiency in Plasma-Derived Medicines

10/19/2021 | 11:21am EST

Grifols inaugurated the first integrated plasma-supply platform in Africa, the start of a robust plasma infrastructure that will bring self-sufficiency to Egypt while facilitating access to plasma products for the broader Middle East and African region, as well as other countries. Innovative in its goals and scope, the alliance that Grifols and Egypt announced in November 2020 is the first ever that pairs a government entity and a private plasma manufacturer to tackle national self-sufficiency. This game-changing initiative could be a blueprint for comparable efforts with other countries to increase local access to plasma and plasma treatments. Paving the way for this milestone in Egypt has been the rapid incorporation of legislation to meet international quality and safety standards. Local donation requirements are now aligned with those of the U.S. FDA, which oversees the most experienced network of plasma collection centers. Also guaranteeing excellence is Grifols' proven reliance on vertically integrated operations, ensuring end-to-end control of the entire plasma procurement and manufacturing process, from donation to finished medicinal product. Facilities in Egypt are expected to be authorized by local authorities as well as international regulatory agencies, such as the European Medicines Agency (EMA) and certified by the International Quality Plasma Program (IQPP) of the Plasma Protein Therapeutics Association (PPTA). Grifols Egypt for Plasma Derivatives, the joint-venture company between Grifols and the NSPO, initially plans to construct and fully equip 20 donation centers throughout the country. Officials from Grifols and the NSPO were in Cairo's Western Giza district to visit the first plasma collection center, housed in a modern two-story complex named 6th of October. It will begin taking plasma donations in November. The platform of plasma-supply centers, located throughout the country and equipped with the most advanced technology, will have a combined future collection volume capacity of 1 million plasma liters annually. This building also includes a testing laboratory for screening plasma and a training and educational area belonging to The Grifols Academy, the company's premier ongoing employee professional education program. The alliance will combine its expertise, technology and resources to construct production facilities for manufacturing hemoderivative medicines in the New Capital, including a plant to fractionate individual plasma proteins with a capacity to process 1 million plasma liters yearly that is expected to double. There will also be a protein purification plant and testing and warehousing operations.


© S&P Capital IQ 2021
All news about GRIFOLS, S.A.
12/08European ADRs Nudge Higher in Wednesday Trading
MT
12/02GRIFOLS S A : receives first certifications for new In Vitro Diagnostics Medical Devices E..
PU
12/02Asset Sale Offer - Launch Announcement
AQ
11/30Grifols Opens Plasma Donor Center in the U.S
CI
11/24GRIFOLS S A : lanza un nuevo servicio de tratamiento a domicilio para pacientes con défici..
PU
11/24GRIFOLS S A : launches new home-care treatment service for patients with alpha-1 antitryps..
PU
11/18European ADRs Move Lower in Thursday Trading
MT
11/17GLOBAL MARKETS LIVE : Tesla, Experian, Roche, Activision, Amazon...
AX
11/17GRIFOLS S A : and GIC obtain authorization for their strategic agreement for USD 1 billion
PU
11/17GRIFOLS S A : November 17, 2021Grifols and GIC obtain authorization for their strategic ag..
PU
More news
Analyst Recommendations on GRIFOLS, S.A.
More recommendations
Financials
Sales 2021 5 289 M 5 983 M 5 983 M
Net income 2021 549 M 621 M 621 M
Net Debt 2021 6 167 M 6 975 M 6 975 M
P/E ratio 2021 19,3x
Yield 2021 1,94%
Capitalization 8 935 M 10 127 M 10 106 M
EV / Sales 2021 2,86x
EV / Sales 2022 2,59x
Nbr of Employees 23 431
Free-Float 79,7%
Chart GRIFOLS, S.A.
Duration : Period :
Grifols, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRIFOLS, S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 15,36 €
Average target price 26,17 €
Spread / Average Target 70,4%
EPS Revisions
Managers and Directors
Raimon Grifols Roura Joint Chief Executive Officer & Executive Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Víctor Grifols Roura Non-Executive Chairman
Xavier Sueiras Gil Chief Information Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
GRIFOLS, S.A.-35.70%10 127
CSL LIMITED7.48%99 422
WUXI BIOLOGICS (CAYMAN) INC.-0.97%55 500
SAMSUNG BIOLOGICS CO.,LTD.10.65%51 558
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-4.14%34 479